WB
H Mk
Endogenous
34 to 36
Mouse IgG1
#P22626
3181
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a human hnRNP B1 protein.
Background
Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) is a member of the hnRNP A/B family of related RNA-binding proteins that bind pre-mRNA and are involved in the processing, metabolism, and transport of nuclear pre-mRNA transcripts (1). Alternative splicing produces transcripts that encode two homologous hnRNP proteins, hnRNPA2 and hnRNPB1, from a single gene sequence (2). Studies demonstrate hnRNP A2/B1 splicing repression across multiple targets (3,4) and that both proteins can bind and protect telomere repeat sequences from DNase digestion (5,6). Altered expression of hnRNP B1 is seen in several forms of cancer, including squamous cell carcinoma, adenocarcinoma, and various forms of lung cancer (7). Overexpression of hnRNP B1 may be associated with inhibition of DNA-PK activity and impaired DNA repair during early stages of cancer development (8). Autoantigens to hnRNP A2/B1 (termed RA33) are associated with rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease (9-11).
- Myer, V.E. and Steitz, J.A. (1995) RNA 1, 171-82.
- Kozu, T. et al. (1995) Genomics 25, 365-71.
- Clower, C.V. et al. (2010) Proc Natl Acad Sci USA 107, 1894-9.
- Moran-Jones, K. et al. (2009) Cancer Res 69, 9219-27.
- Moran-Jones, K. et al. (2005) Nucleic Acids Res 33, 486-96.
- Kamma, H. et al. (2001) Biochem Biophys Res Commun 280, 625-30.
- Hamasaki, M. et al. (2001) Anticancer Res 21, 979-84.
- Iwanaga, K. et al. (2005) Biochem Biophys Res Commun 333, 888-95.
- Fritsch, R. et al. (2002) J Immunol 169, 1068-76.
- Fritsch-Stork, R. et al. (2006) Arthritis Res Ther 8, R118.
- Skriner, K. et al. (1997) J Clin Invest 100, 127-35.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.